Objective
WWOX
, a well-established tumor suppressor, is frequently lost in cancer and plays important roles in DNA damage response and cellular metabolism.
Methods
We re-analyzed several genome-wide association studies (GWAS) using the
Type 2 Diabetes Knowledge Portal
website to uncover WWOX's association with metabolic syndrome (MetS). Using several engineered mouse models, we studied the effect of somatic WWOX loss on glucose homeostasis.
Results
Several
WWOX
variants were found to be strongly associated with MetS disorders. In mouse models, somatic ablation of
Wwox
in skeletal muscle (
Wwox
ΔSKM
) results in weight gain, glucose intolerance, and insulin resistance. Furthermore,
Wwox
ΔSKM
mice display reduced amounts of slow-twitch fibers, decreased mitochondrial quantity and activity, and lower glucose oxidation levels. Mechanistically, we found that WWOX physically interacts with the cellular energy sensor AMP-activated protein kinase (AMPK) and that its loss is associated with impaired activation of AMPK, and with significant accumulation of the hypoxia inducible factor 1 alpha (HIF1α) in SKM.
Conclusions
Our studies uncover an unforeseen role of the tumor suppressor WWOX in whole-body glucose homeostasis and highlight the intimate relationship between cancer progression and metabolic disorders, particularly obesity and type-2 diabetes.
Subject areas
Genetics, Metabolic Syndrome, Diabetes.